Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Elotuzumab · Empliciti, BMS-901608

Monoclonal antibody · Immune activation, directed at SLAMF7 · developed by Bristol Myers Squibb

Approved FDA, Nov 2015
BMY Developer

What is Elotuzumab?

Elotuzumab is a humanized IgG1 monoclonal antibody that binds SLAMF7, a protein expressed on myeloma cells, NK cells and plasma cells. It directly activates NK cells and mediates killing of myeloma cells through antibody-dependent cellular cytotoxicity and phagocytosis. It is studied in multiple myeloma, including refractory disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Empliciti, BMS-901608, HULUC63, PDL-063
Drug type
Monoclonal antibody
Targets
SLAMF7
Mechanism
Immune activation, directed at SLAMF7
Pathways
NK cell activation via SLAMF7 pathway, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis
Therapy area
Oncology
Developer
Bristol Myers Squibb (BMY)
FDA status
Approved as Empliciti (November 30, 2015), BLA761035 · FDA label
UNII
1351PE5UGS

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 22, 2022). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Multiple MyelomaMyelomaRefractory Multiple Myeloma

More from Bristol Myers Squibb

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Elotuzumab

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.